诺和诺德将公司名缩短为“Novo”并调整标识，配合CEO Doustdar的品牌重塑，为下周资本市场日预热

Novo Nordisk A/S will shorten its name to just Novo in a bid to become more recognizable in its obesity market war with Eli Lilly & Co.

The drugmaker is also tweaking its logo, shifting its trademark bull to look to the right, it said in a statement Monday. The change comes as Lilly also increasingly leans on a single-name identity, dropping the word “Eli” from its marketing materials.

Chief Executive Officer Mike Doustdar is pushing Novo to become leaner and more competitive as the Danish company tries to wrest back a larger share of the obesity market it pioneered from Lilly.

For Novo, stripping “Nordisk” from the name removes a link to the company’s history. The drugmaker was founded as Nordisk Insulinlaboratorium in 1923, bringing the newly-discovered technology for producing insulin to Denmark. Former employees founded the rival Novo branch two years later, and the two merged in 1989.

Doustdar will present the new brand identity to employees tomorrow. Next week, he will face investors at the company’s annual capital markets day.

“A new name, logo, and slogan must be accompanied by a true strategic change,” Evan David Seigerman, an analyst at BMO Capital Markets, wrote in a note. Next week’s meeting “must bring substance and strategic direction to support a sustainable organization into the 2030s and beyond.”